FDA Finally Approves Avastin In First-Line Ovarian Cancer

13 Jun 2018

• By Emily Hayes

Genentech says it worked closely with the agency to bring the drug to women with earlier-stage disease.

Eight years after pivotal data were presented publicly supporting its use in first-line advanced ovarian cancer after surgery, Roche's VEGF inhibitor Avastin finally has been approved by the US FDA for this indication.

The June 13 approval covers treatment with Avastin (bevacizumab) in combination with chemotherapy (carboplatin and paclitaxel), followed by Avastin as...